Immunogenicity & Safety of an Investigational Quadrivalent Meningococcal

Status Completed

Clinical Trial Summary

The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed vaccine MENVEO® in adolescents 10 to 17 years of age in the United States (US). This study also evaluated the immunogenicity and safety of MenACYW Conjugate vaccine when given alone compared to when given concomitantly with tetanus, diphtheria, acellular pertussis (Tdap) vaccine and human papilloma virus (HPV) vaccine. Primary objective: - To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine when MenACYW Conjugate vaccine was given alone compared to those when MENVEO vaccine was given alone. Secondary objective: - To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine, when MenACYW Conjugate vaccine was given concomitantly with Tdap and HPV vaccines, compared to those when it was given alone. - To evaluate the antibody responses to the antigens present in Tdap vaccine, when Tdap vaccine was given concomitantly with MenACYW Conjugate vaccine and HPV vaccine, compared to those when Tdap vaccine was given with HPV vaccine only. - To evaluate the antibody responses to the antigens present in HPV vaccine after the 3-dose series, when the first dose of HPV vaccine is given concomitantly with MenACYW Conjugate vaccine and Tdap vaccine, compared to those when the first dose of HPV vaccine is given with Tdap vaccine only. Observational objective: - To describe the safety profile of MenACYW Conjugate vaccine, compared to that of the licensed vaccine MENVEO®, and when MenACYW Conjugate vaccine was given with Tdap and HPV vaccines.

Clinical Trial Description

Healthy adolescents were randomized and received a single dose of their assigned vaccines. They were assessed for immunogenicity at baseline (pre-vaccination) and at 30 days post-vaccination. Safety information were collected post-vaccination and throughout the entire study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02199691
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 2
Start date	July 22, 2014
Completion date	October 2, 2015

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03445416` - Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men	N/A
Completed	`NCT02526394` - Pertussis and Meningitis C Concomitant Vaccination in Adolescents	Phase 4
Completed	`NCT01442675` - Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine	Phase 2
Completed	`NCT00539032` - Immunology and Safety of Menactra® in Children in Saudi Arabia	Phase 3
Terminated	`NCT00428051` - Colombia Epidemiologic Surveillance Study	N/A
Recruiting	`NCT05496673` - Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda	N/A
Completed	`NCT02003495` - Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine	Phase 3
Recruiting	`NCT00901602` - Lebanese Interhospital Pneumococcal Surveillance Program
Completed	`NCT00850603` - Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®	Phase 4
Completed	`NCT02591290` - Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects	Phase 4
Completed	`NCT03112031` - Treatment With Tamoxifen in Cryptococcal Meningitis	Phase 2
Completed	`NCT02881957` - Hypovitaminosis D in Neurocritical Patients	Phase 2/Phase 3
Completed	`NCT06334796` - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology	Early Phase 1
Completed	`NCT03378258` - Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Recruiting	`NCT05637645` - Different Approaches of Spinal Anesthesia in Patients Undergoing Cesarean Section	N/A
Completed	`NCT02841254` - Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies	N/A
Completed	`NCT02003313` - Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine	Phase 3
Recruiting	`NCT01619462` - Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children	Phase 3
Completed	`NCT01239043` - Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination	Phase 2
Completed	`NCT00495690` - Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms